Home > Publications database > Pre-surgery adhesion molecules and angiogenesis biomarkers are differently associated with outcomes in colon and rectal cancer: Results from the ColoCare Study. > print

001     180230
005     20240229145610.0
024 7 _ |a pmid:35667092
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a 10.1158/1055-9965.EPI-22-0092
|2 doi
024 7 _ |a DOI: 10.1158/1055-9965.EPI-22-0092
|2 doi
024 7 _ |a altmetric:129365544
|2 altmetric
037 _ _ |a DKFZ-2022-01181
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ose, Jennifer
|b 0
245 _ _ |a Pre-surgery adhesion molecules and angiogenesis biomarkers are differently associated with outcomes in colon and rectal cancer: Results from the ColoCare Study.
260 _ _ |a Philadelphia, Pa.
|c 2022
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1662122294_29854
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Aug 2;31(8):1650-1660
520 _ _ |a Cell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion-molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer (CRC).In pre-surgery serum from n=426 CRC patients (stage I-III) we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A, and -D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed hazard ratios (HR) and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses.N=65 (15%) were deceased, 59 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 - 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared to patients in the bottom tertile, e.g., risk of recurrence HRQ3-Q1:13.92 (1.72, 112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HRlog2: 3.26; 95% CI: 1.58-6.70) compared to no association for colon cancer (HRlog2: 0.78; 95% CI: 0.35-1.73; pheterogenity =0.01).Adhesion molecules and angiogenesis biomarkers are independent prognostic markers for CRC, with differences by tumor site.There is need for tailored treatment for colon and rectal cancer.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Gigic, Biljana
|b 1
700 1 _ |a Hardikar, Sheetal
|0 0000-0003-0292-6168
|b 2
700 1 _ |a Lin, Tengda
|0 0000-0001-5147-8432
|b 3
700 1 _ |a Himbert, Caroline
|0 0000-0003-4084-8340
|b 4
700 1 _ |a Warby, Christy A
|0 0000-0003-1772-8332
|b 5
700 1 _ |a Peoples, Anita R
|0 0000-0003-3645-3960
|b 6
700 1 _ |a Lindley, Clara L
|0 0000-0001-6156-254X
|b 7
700 1 _ |a Boehm, Juergen
|0 0000-0001-8639-3543
|b 8
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 9
|u dkfz
700 1 _ |a Figueiredo, Jane C
|0 0000-0001-8040-3341
|b 10
700 1 _ |a Toriola, Adetunji T
|0 0000-0003-1079-2606
|b 11
700 1 _ |a Siegel, Erin M
|0 0000-0003-1779-2510
|b 12
700 1 _ |a Li, Christopher I
|0 0000-0003-1543-0743
|b 13
700 1 _ |a Ulrich, Alexis
|0 0000-0003-1469-2186
|b 14
700 1 _ |a Schneider, Martin
|b 15
700 1 _ |a Shibata, David
|0 0000-0002-5670-423X
|b 16
700 1 _ |a Ulrich, Cornelia M
|0 0000-0001-7641-059X
|b 17
773 _ _ |a 10.1158/1055-9965.EPI-22-0092
|0 PERI:(DE-600)2036781-8
|n 8
|p 1650-1660
|t Cancer epidemiology, biomarkers & prevention
|v 31
|y 2022
|x 1055-9965
909 C O |p VDB
|o oai:inrepo02.dkfz.de:180230
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2021
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-10
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21